ICO THERAPEUTICS ICOTF news, videos and press releases
For more news please use our advanced search feature.
ICO THERAPEUTICS ICOTF - More news...
ICO THERAPEUTICS ICOTF - More news...
- Satellos Bioscience Announces Partnership with Jesse's Journey
- Satellos Bioscience Announces Second Quarter 2021 Financial Results and MD&A
- Satellos Bioscience Announces High Resolution Crystal Structure of Duchenne Drug Target
- Satellos Bioscience Announces Joint Development Agreement with NW PharmaTech Limited for Oral CBD
- Satellos and iCo Announce Completion of Reverse Takeover
- iCo Therapeutics Inc. Announces Shareholder Approval of Business Combination with Satellos Bioscience Inc.
- iCo Therapeutics Inc. Announces TSX Venture Exchange Conditional Approval and Provides Update Regarding Business Combination with Satellos Bioscience Inc.
- iCo Therapeutics Announces First Quarter 2021 Financial Results
- iCo Therapeutics Subsidiary to present Oral Amphotericin B / SARS-Cov-2 Research Results at National Pharmaceutical Sciences Meeting
- iCo Therapeutics Announces 2020 Year End Financial Results and Resignation of Susan Koppy
- iCo Therapeutics Inc. Announces Closing of Upsized Subscription Receipt Private Placement
- iCo Therapeutics Inc. Announces Upsized Subscription Receipt Private Placement
- iCo Therapeutics Inc. Agrees to a Business Combination with Satellos Bioscience Inc.
- iCo Therapeutics, Inc. Announces Agreement for in Vivo Testing of iCo-019 on SARS-CoV-2
- iCo Therapeutics Inc. Announces Warrant Exercises
- iCo Therapeutics Inc: Unaware of Any Material Change
- iCo Therapeutics Inc. Proposes to Re-Price Warrants
- iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical
- iCo Therapeutics Announces Third Quarter 2020 Financial Results
- iCo Therapeutics Announces Option Grants
- iCo Therapeutics Inc. Announces That Oral Amphotericin B (iCo-019) Results Will Be Highlighted During the American Association of Pharmaceutical Scientists (AAPS) Virtual Meeting October 26 - November 3rd, 2020
- iCo Therapeutics Announces Second Quarter 2020 Financial Results
- iCo Therapeutics Inc. Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases Journal
- iCo Therapeutics Announces First Quarter 2020 Financial Results
- iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo-019) Results to be Presented at Prestigious American Pharmaceutical Sciences Meeting and Discussion Updates
- iCo Therapeutics Inc. Announces Q1 Interim Filing Update
- iCo Therapeutics Announces 2019 Year End Financial Results
- iCo Therapeutics Inc. Announces Annual Filing Update
- iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research
- iCo Therapeutics Announces Leadership Changes
